# Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

> **NCT04967443** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 72 (actual)

## Conditions studied

- Hypertension
- Heart Failure

## Interventions

- **DRUG:** Prazosin HCl 2mg
- **DRUG:** Prazosin HCl 1 mg
- **DRUG:** Prazosin HCl 5 mg

## Key facts

- **NCT ID:** NCT04967443
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-22
- **Primary completion:** 2022-02-15
- **Final completion:** 2022-02-15
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967443, "Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04967443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*